What Глемонт Treats: Main Uses and Benefits

Глемонт (Montelukast) is commonly used for managing conditions involving chronic respiratory conditions associated with acute or disruptive episodes, and may assist with providing essential support for patients struggling with persistent airway inflammation and episodic symptoms. The medication's core therapeutic benefit contributes to improved comfort and helps maintain a sense of stability by addressing specific symptom domains.

Its primary uses include managing symptoms related to physical discomfort from chronic asthma, supporting the patient in managing symptoms of seasonal and perennial allergic rhinitis, and is used for managing symptoms associated with exercise-triggered breathing difficulty.

Managing Symptoms Related to Chronic Asthma

Глемонт is commonly used across conditions characterized by periods of heightened symptoms, such as persistent asthma. It is applied in addressing symptom clusters related to physical discomfort, including wheezing and chest tightness, which may interfere with daily functioning. This supports the patient during difficult episodes by easing distress and may help maintain a sense of stability when symptoms are more noticeable.

Supportive Management for Allergic Nasal Symptoms

This medication is applied in addressing symptoms related to inflammatory or irritative states associated with allergic rhinitis, including nasal congestion and persistent sneezing. When these groups of symptoms appear or intensify seasonally, the medication contributes to improved comfort and supports patients during episodes of heightened discomfort.

---

Quick Fact: Supportive Management for Respiratory Discomfort Глемонт is commonly used across therapeutic domains where additional symptomatic support is needed for managing both lower airway symptoms (asthma) and upper airway symptoms (allergic rhinitis), assisting with maintaining functional stability during periods of heightened symptoms.

Who Can and Cannot Use Глемонт? Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and adolescents 15 years and older; children 12 months and older for chronic asthma; children 6 months and older for perennial allergic rhinitis.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Montelukast or any component.
Age-related eligibility rules	Safety and effectiveness are not established for asthma in children younger than 12 months or for perennial allergic rhinitis in children younger than 6 months.
Condition-specific eligibility rules	No dosage adjustment is necessary for renal impairment or mild-to-moderate hepatic impairment. Use in severe hepatic impairment is limited due to a lack of available data.
Pregnancy and lactation eligibility status	Use during pregnancy and breastfeeding is permitted only if it is considered to be clearly essential.
Eligibility-related restrictions	Contraindicated for the treatment of acute asthma attacks or status asthmaticus. The chewable tablet is not eligible for patients with phenylketonuria (PKU).

---

Official Eligibility Statements

• Глемонт is absolutely contraindicated in patients with hypersensitivity to the drug or any component.
• It must not be used for acute asthma attacks; it is solely for long-term preventative management.
• The medicine is not eligible for patients with phenylketonuria (PKU) if using the chewable formulation.

---

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use Глемонт by establishing clear absolute contraindications and acute-use prohibitions. Eligibility is further structured by specific age minimums for each condition and by explicit conditional restrictions related to physiological status, such as pregnancy and severe hepatic impairment, keeping use strictly within documented population boundaries.

Interactions with other medicines and products

The official regulatory profile for Глемонт (Montelukast) details specific pharmacokinetic changes mediated by drug-metabolizing enzymes and outlines particular restrictions.

---

Metabolic and Exposure Alterations

Co-administration with certain enzyme-inducing medicines, such as Rifampicin and Phenobarbital, is officially documented to reduce the systemic exposure of Montelukast, with the Area Under the Curve (AUC) decreasing by approximately 40%. Conversely, Gemfibrozil, a potent inhibitor of the CYP 2C8 enzyme, significantly increases Montelukast systemic exposure, causing AUC to rise approximately 4.4-fold. Regulatory documents state that Montelukast is not anticipated to clinically alter the metabolism of many other co-administered medicinal products, including Theophylline, Warfarin, and most Oral Contraceptives.

---

Restrictions and Conditions

No specific drug-drug combinations are formally classified as contraindicated based on interaction risk. However, a pharmacodynamic restriction requires that patients with known aspirin sensitivity must continue to avoid Aspirin and other Non-Steroidal Anti-Inflammatory Agents (NSAIDs). For the oral granule formulation only, a high-fat meal reduces the maximum plasma concentration ( C max) by 35%. Additionally, official labeling notes that patients with mild-to-moderate hepatic impairment exhibit a 41% higher mean AUC due to altered metabolism.

Глемонт is a selective modulator of the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL)/RANK/Osteoprotegerin (OPG) pathway. It acts specifically by binding to the RANKL protein. This binding prevents the interaction of RANKL with its receptor, RANK, which is expressed on the surface of osteoclast precursor cells and mature osteoclasts.

The inhibition of the RANKL-RANK signaling axis interrupts the intracellular cascade required for the differentiation, activation, and survival of osteoclasts. As a direct molecular consequence, Глемонт decreases the rate of bone resorption. This action modulates the overall dynamics of bone remodeling by shifting the balance away from degradation and towards formation.

How to Use Глемонт

Глемонт (Montelukast) is administered orally and is intended for once-daily, continuous use, rather than immediate symptom relief. The correct usage protocol is strictly determined by age and the specific formulation. All doses can be taken with or without food.

Dosage and Frequency Guidelines

Administration for chronic asthma and for the combination of chronic asthma and allergic rhinitis requires the medicine to be taken in the evening. For allergic rhinitis alone, the time of day may be individualized. The standard dose of 10 mg is prescribed for adults and adolescents 15 years and older. Pediatric patients require lower strengths: 5 mg for ages 6 to 14 years, and 4 mg for ages 2 to 5 years. Глемонт should be continued daily, even during periods when symptoms are controlled.

Administration for Exercise-Induced Difficulty

For exercise-induced breathing difficulty prophylaxis, a separate 10 mg dose is taken as a single administration at least 2 hours before exercise. Importantly, patients already on a daily Глемонт regimen for another chronic indication should not take an additional dose for this purpose on the same day, as only one dose is permitted every 24 hours.

Form-Specific Handling Instructions

Form	Administration Rule (Non-Safety Constraint)
Chewable Tablets	Must be chewed completely before swallowing.
Oral Granules	Must be administered within 15 minutes of opening the packet. May be mixed with approved soft foods (e.g., applesauce, rice) or 5 mL of baby formula, and must not be stored for later use.

No dose adjustment is required for older adults or in patients with mild-to-moderate renal or hepatic impairment.

Research evidence / Overview of Studies for Глемонт (Montelukast)

The clinical understanding of Глемонт (Montelukast) is based on a large body of official research, including numerous Randomized Controlled Trials (RCTs), comparative studies, and extensive Meta-Analyses conducted and reviewed by regulatory bodies worldwide. These studies were carried out to evaluate the medicine's use as a long-term intervention for conditions associated with cycles of stability and flare-ups in respiratory conditions. Findings describe group patterns and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.

---

Evidence for Long-Term Management of Chronic Asthma

Research was conducted using high-quality RCTs and large systematic reviews exploring how symptoms change over time in patients with persistent asthma. Outcomes related to functional physiological measures (like lung volume ( FEV1)) and outcomes describing episodic or acute changes (such as the frequency of asthma flare-ups) were measured. Findings describe patterns observed in the measured functional outcomes and in the rates of acute episodes reported across study groups when compared to placebo.

Comparative studies reported varying patterns in functional outcomes between inhaled corticosteroids (ICS) and Глемонт monotherapy, and research has explored its use as an add-on therapy alongside ICS. A key aspect of the research is the study of comparative outcomes versus standard ICS therapy; findings show variation across different populations and severity levels, which is a key area of ongoing study. Furthermore, long-term outcomes are not fully established for all potential comparison scenarios, as studies often focus on a defined time interval of several months to one year.

---

Evidence for Supportive Management of Allergic Rhinitis

The evidence for using Глемонт in conditions involving periods of heightened symptoms related to allergic rhinitis was evaluated in short-term, placebo-controlled trials. Studies monitored patient-reported outcomes describing perceived discomfort, such as Total Nasal Symptom Scores (TNSS). Studies reported measurements of changes in these nasal symptom scores when compared to placebo groups. Studies reported different measured outcomes for nasal symptoms when compared to topical nasal steroids. Follow-up durations were limited in many of the seasonal studies, as research explores short-term symptom changes relevant to a single pollen season.

---

Evidence for Preventing Breathing Difficulty Related to Exercise

Researchers examined temporary physiological imbalance using specific RCTs that included standardized exercise challenge tests. The outcomes captured were functional measures, specifically the maximum percent drop in FEV1. Research observed patterns related to the measured drop in FEV1 across the Montelukast group and the placebo group following the challenge. The research focuses primarily on the acute, physiological measurement observed in the laboratory setting.

---

What Remains Uncertain About the Research Evidence

A key limitation is the lack of fully established, consistent, long-term comparative data versus inhaled corticosteroids as a first-line therapy for persistent asthma. Regulatory bodies monitor observational settings, which included surveillance for rare events not fully captured in the primary efficacy RCTs. Data are still emerging from large-scale post-market studies, which report on a wide range of neuropsychiatric events that were observed in some patient groups and are the subject of continued regulatory attention.

Key Studies & References

1. NIH National Library of Medicine: Drug Record - Montelukast

Common questions about Глемонт (FAQ)

Q: How quickly does the effect of Глемонт typically begin?

A: Official product information shows that the active ingredient, Montelukast, is absorbed quickly after being taken, reaching its highest level in the blood within 2 to 4 hours. However, this medication is designed for long-term, continuous daily use to prevent problems, and it is not intended to provide immediate relief for sudden or acute symptoms.

---

Q: How long does one dose of Глемонт usually last in the body?

A: Regulatory documents indicate that the average time it takes for half of the medication to be eliminated from the body (half-life) is between 2.7 and 5.5 hours in healthy young adults. Глемонт is intended for once-daily administration to help maintain consistent protective levels in the body over time.

---

Q: What happens if I forget to take a dose of Глемонт?

A: Patient guidance, based on regulatory instructions, advises that if a dose is missed, the patient should simply take the next scheduled dose at the regular time. Official guidance indicates that a double dose should not be taken to compensate for a single missed dose.

---

Q: Do people typically stop taking Глемонт abruptly or taper off?

A: Official safety warnings advise that if a person develops new or worsening mental health symptoms (neuropsychiatric events), discontinuation should be considered immediately and a healthcare professional should be consulted. This specific safety guidance on urgent discontinuation does not typically mention a mandatory tapering schedule.

---

Q: How does the general purpose of Глемонт differ from similar treatments I've heard about?

A: Глемонт belongs to a specific class of drugs called Leukotriene Receptor Antagonists (LTRAs), which work by blocking the action of inflammatory chemicals called leukotrienes. This mechanism is chemically distinct from other common preventative treatments like Inhaled Corticosteroids (ICS) or from rescue inhalers, as its role is long-term daily protection.

---

Q: What kind of research has been done on the long-term effects of Глемонт?

A: Research includes both formal studies (Randomized Controlled Trials) and ongoing post-market surveillance, which is regulatory monitoring after the drug is approved. The data gathered from these long-term surveillance studies led to a strengthened warning regarding the potential for serious neuropsychiatric events observed across all age groups.

---

Q: Is Глемонт used for things other than its main indication?

A: According to the official product label, Глемонт is indicated for the long-term prevention and treatment of asthma and for relieving symptoms related to seasonal and perennial allergic rhinitis (allergies).

---

Q: Can Глемонт cause changes in sleep patterns?

A: Official safety information describes sleep-related issues as potential side effects, which fall under the category of neuropsychiatric events. These events can include insomnia (trouble sleeping), sleepwalking, and experiencing bad or vivid dreams.

---

Q: Is it common to feel a little dizzy when first starting Глемонт?

A: Dizziness has been reported in post-marketing experience. However, based on regulatory frequency classifications, dizziness is not listed among the most common adverse reactions reported by patients in clinical trials.

---

Q: What are some of the most frequently reported side effects of Глемонт?

A: The most frequently reported effects listed in official documents (Very Common to Common) include upper respiratory infection, headache, and gastrointestinal issues such as diarrhoea, nausea, and vomiting.

---

Q: Does Глемонт interact with common pain relievers like ibuprofen?

A: Formal studies on Montelukast do not typically show major drug-drug interactions with common pain relievers. However, patients with a known aspirin sensitivity are specifically advised in regulatory warnings to continue avoiding aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs).

---

Q: Can I take Глемонт if I am already taking supplements?

A: Official guidance warns that Montelukast can interact with certain herbal products, such as St. John's wort, which may reduce the drug’s intended effect. Patients should inform their healthcare provider about all vitamins, supplements, and herbal products they are taking.

---

Q: What is the risk of dependence or addiction described for Глемонт?

A: Глемонт is not classified as a controlled substance by regulatory bodies. The official documentation for the medication does not include warnings or statements regarding any potential for physical dependence or addiction.

---

Q: Has Глемонт been studied in children or adolescents?

A: Yes, regulatory agencies reviewed data from numerous clinical trials, including randomized controlled trials, specifically conducted to establish the safety and effectiveness of Глемонт for use in pediatric patients. Specific age minimums for its use are defined for both chronic asthma and perennial allergic rhinitis.

---

Q: Is a prescription required to get Глемонт?

A: Yes. Глемонт is classified as a prescription drug in all its available regulated forms, including tablets, chewable tablets, and oral granules.

---

Q: Is Глемонт available in generic form?

A: Yes. Regulatory agencies like the FDA have approved and listed multiple generic versions of the active ingredient, montelukast sodium, ensuring broader availability.

---

Q: Can Глемонт cause changes in appetite or weight?

A: Appetite and weight changes are not listed among the frequently reported adverse reactions. However, weight gain has been reported in the post-marketing period as an event of unknown frequency.

---

Q: What should a person do if they suspect an allergic reaction to Глемонт?

A: Hypersensitivity (severe allergy) to the drug is an absolute contraindication. Official patient safety information indicates that if a person experiences signs of an allergic reaction, such as swelling, rash, or difficulty breathing, seeking immediate medical attention is necessary.

---

Q: Do official sources mention any long-term physical changes associated with Глемонт?

A: Regulatory sources continuously monitor long-term data via post-market surveillance. The most emphasized long-term warning focuses on serious neuropsychiatric events. Official documents do not detail specific long-term physical changes other than those related to rare systemic conditions like vasculitis.

---

Q: What common misunderstandings do people have about how Глемонт works?

A: A key clarification in patient resources is that this medication is a preventer (prophylactic) intended for long-term daily control of symptoms. Official guidelines indicate it should not be used to treat or reverse an acute asthma attack.

---

Q: Does Глемонт have a 'black box' warning, according to the FDA or similar bodies?

A: Yes. The U.S. Food and Drug Administration (FDA) requires a Boxed Warning on the official prescribing information. This warning is used to highlight the risk of serious neuropsychiatric events, including suicidal thoughts and actions.

---

Q: Does Глемонт affect fertility?

A: Official regulatory documents, including those reviewed for women who are pregnant or breastfeeding, specifically indicate that there is no evidence suggesting that Глемонт affects male or female fertility.

Storage and Disposal Requirements

Official regulatory information provides specific instructions for the storage and disposal of Glemont (Montelukast) to ensure product stability and safety.

Storage Classification	Requirement
Temperature	Store below 25^circC (Controlled Room Temperature is generally permitted).
Protection	Keep in the original package to protect from light and moisture.
Handling Prohibitions	Do not freeze. Do not store above the maximum temperature specified on the label.
Child Safety	Keep out of the reach of children and sight of children.
Disposal	Any unused or expired product must be disposed of in accordance with local regulatory requirements. Disposal should not be through wastewater (drains/toilet) or routine household waste unless otherwise instructed by a local official drug take-back program or regulator.